ATE332696T1 - Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen - Google Patents
Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosenInfo
- Publication number
- ATE332696T1 ATE332696T1 AT98950911T AT98950911T ATE332696T1 AT E332696 T1 ATE332696 T1 AT E332696T1 AT 98950911 T AT98950911 T AT 98950911T AT 98950911 T AT98950911 T AT 98950911T AT E332696 T1 ATE332696 T1 AT E332696T1
- Authority
- AT
- Austria
- Prior art keywords
- glycocorticoid
- disorders
- treating psychoses
- psychoses caused
- caused
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003862 glucocorticoid Substances 0.000 title 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6097397P | 1997-10-06 | 1997-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE332696T1 true ATE332696T1 (de) | 2006-08-15 |
Family
ID=22032889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98950911T ATE332696T1 (de) | 1997-10-06 | 1998-10-05 | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6150349A (de) |
| EP (1) | EP1023074B1 (de) |
| JP (3) | JP2001518509A (de) |
| KR (2) | KR100804558B1 (de) |
| CN (3) | CN1919199A (de) |
| AT (1) | ATE332696T1 (de) |
| AU (1) | AU747956B2 (de) |
| CA (1) | CA2302586C (de) |
| CY (1) | CY1106330T1 (de) |
| DE (1) | DE69835225T2 (de) |
| DK (1) | DK1023074T3 (de) |
| ES (1) | ES2268792T3 (de) |
| IL (2) | IL135469A0 (de) |
| NO (1) | NO327233B1 (de) |
| NZ (1) | NZ503250A (de) |
| PT (1) | PT1023074E (de) |
| WO (1) | WO1999017779A1 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0903146A1 (de) * | 1997-09-23 | 1999-03-24 | Applied Research Systems ARS Holdings N.V. | 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid |
| GB9915625D0 (en) * | 1999-07-02 | 1999-09-01 | Cortendo Ab | Method |
| US6620802B1 (en) * | 1999-11-23 | 2003-09-16 | Corcept Therapeutics, Inc. | Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
| PT1325022E (pt) * | 2000-09-18 | 2006-12-29 | Applied Research Systems | Método para a preparação de 21-hidroxi-6, 19-oxido-progesterona (210h-60p) |
| CA2440605C (en) * | 2001-03-23 | 2012-01-10 | Corcept Therapeutics, Inc. | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| WO2002096433A1 (en) * | 2001-05-04 | 2002-12-05 | Corcept Therapeutics, Inc. | Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| US7163934B2 (en) | 2001-05-04 | 2007-01-16 | Corcept Therapeutics, Inc. | Methods for treating delirium glucocorticoid receptor-specific antagonists |
| DK1408981T3 (da) * | 2001-07-23 | 2009-01-12 | Corcept Therapeutics Inc | Fremgangsmåder til forebyggelse af vægtforögelse som fölge af antipsykotiske midler |
| CA2459033C (en) * | 2001-08-31 | 2012-05-22 | Corcept Therapeutics, Inc. | Methods for inhibiting cognitive deterioration in adults with down's syndrome |
| KR20050038580A (ko) * | 2001-10-26 | 2005-04-27 | 악조 노벨 엔.브이. | 주요 우울 장애의 치료에 사용되는(11β,17β)-11-(1,3-벤조디옥솔-5-일)-17-히드록시-17-(1-프로피닐)-에스트라-4,9-디엔-3-온의 용도 |
| AU2002366217A1 (en) * | 2001-11-23 | 2003-06-10 | Akzo Nobel N.V. | Treatment of major depressive disorder using glucocorticoid receptor antagonists |
| US7326697B2 (en) * | 2002-04-29 | 2008-02-05 | Corcept Therapeutics, Inc. | Methods for increasing the therapeutic response to electroconvulsive therapy |
| CN1665515A (zh) * | 2002-07-02 | 2005-09-07 | 科塞普特治疗公司 | 治疗与干扰素α治疗相关的精神病的方法 |
| WO2004054587A1 (en) * | 2002-12-18 | 2004-07-01 | University Of Zurich | Treatment of neuro-psychiatric disorders |
| CA2514966A1 (en) * | 2003-02-04 | 2004-08-19 | Corcept Therapeutics, Inc. | Antiglucocorticoids for the treatment of postpartum psychosis |
| US8097606B2 (en) | 2003-07-23 | 2012-01-17 | Corcept Therapeutics, Inc. | Antiglucocorticoids for the treatment of catatonia |
| GB0400031D0 (en) | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
| US20090156565A1 (en) * | 2004-12-03 | 2009-06-18 | The Children's Hospital Of Philadelphia | Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug |
| CN100588393C (zh) * | 2004-12-15 | 2010-02-10 | 上海三合生物技术有限公司 | 赛米司酮类用于治疗抑郁症的用途 |
| US20060229505A1 (en) * | 2005-04-08 | 2006-10-12 | Mundt James C | Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy |
| EP2012796A4 (de) * | 2006-05-02 | 2010-08-11 | Corcept Therapeutics Inc | Verwendung eines glucocorticoidrezeptor-ii-antagonisten zur behandlung von depressionen bei mit il-2 behandelten patienten |
| EP1987814A1 (de) * | 2007-04-30 | 2008-11-05 | Exelgyn | Pharmazeutische Mifepristonzusammensetzungen und Herstellungsverfahren dafür |
| RU2327448C1 (ru) | 2007-05-23 | 2008-06-27 | Виктор Иванович Рощин | Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов |
| AU2008265898B2 (en) * | 2007-06-15 | 2013-11-28 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties |
| EP2576582B1 (de) * | 2010-05-26 | 2019-09-18 | Corcept Therapeutics, Inc. | Behandlung von muskeldystrophie |
| US8658128B2 (en) | 2011-02-03 | 2014-02-25 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| CN107530435A (zh) * | 2015-03-02 | 2018-01-02 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤 |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| PH12017502099B1 (en) * | 2015-05-18 | 2023-08-30 | Corcept Therapeutics Inc | Methods for diagnosing and assessing treatment for cushing's syndrome |
| WO2018074371A1 (ja) * | 2016-10-21 | 2018-04-26 | シチズン時計株式会社 | 検出装置 |
| EP3941460B1 (de) | 2019-03-18 | 2025-10-15 | Nieman, Lynnette K. | Mifepristone zur verwendung bei der verbesserung der insulinempfindlichkeit |
| WO2021119432A1 (en) | 2019-12-11 | 2021-06-17 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| WO2023033900A1 (en) * | 2021-09-06 | 2023-03-09 | Slayback Pharma Llc | Pharmaceutical compositions of mifepristone |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| US5348729A (en) * | 1988-11-30 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Evaluative means for detecting inflammatory reactivity |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| IL118974A (en) * | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| FR2739029B1 (fr) * | 1995-09-21 | 1997-11-21 | Roussel Uclaf | Nouvelle application therapeutique des composes antimineralo-corticoides |
| JP2000511404A (ja) * | 1996-04-09 | 2000-09-05 | ビー・テイー・ジー・インターナシヨナル・リミテツド | 神経精神、免疫又は内分泌障害を治療するための７α置換ステロイドの使用 |
| FR2757400B1 (fr) * | 1996-12-19 | 1999-12-17 | Hoechst Marion Roussel Inc | Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs |
-
1998
- 1998-10-05 AT AT98950911T patent/ATE332696T1/de active
- 1998-10-05 EP EP98950911A patent/EP1023074B1/de not_active Expired - Lifetime
- 1998-10-05 JP JP2000514650A patent/JP2001518509A/ja not_active Withdrawn
- 1998-10-05 IL IL13546998A patent/IL135469A0/xx active IP Right Grant
- 1998-10-05 DE DE69835225T patent/DE69835225T2/de not_active Expired - Lifetime
- 1998-10-05 KR KR1020007003683A patent/KR100804558B1/ko not_active Expired - Fee Related
- 1998-10-05 WO PCT/US1998/020906 patent/WO1999017779A1/en not_active Ceased
- 1998-10-05 CN CNA2006101003657A patent/CN1919199A/zh active Pending
- 1998-10-05 KR KR1020077003769A patent/KR100840957B1/ko not_active Expired - Fee Related
- 1998-10-05 NZ NZ503250A patent/NZ503250A/en not_active IP Right Cessation
- 1998-10-05 DK DK98950911T patent/DK1023074T3/da active
- 1998-10-05 CA CA002302586A patent/CA2302586C/en not_active Expired - Fee Related
- 1998-10-05 CN CNA200410039908XA patent/CN1528315A/zh active Pending
- 1998-10-05 PT PT98950911T patent/PT1023074E/pt unknown
- 1998-10-05 CN CNB988097923A patent/CN1187053C/zh not_active Expired - Fee Related
- 1998-10-05 ES ES98950911T patent/ES2268792T3/es not_active Expired - Lifetime
- 1998-10-05 AU AU96832/98A patent/AU747956B2/en not_active Ceased
-
1999
- 1999-02-04 US US09/244,457 patent/US6150349A/en not_active Expired - Lifetime
-
2000
- 2000-04-04 IL IL135469A patent/IL135469A/en not_active IP Right Cessation
- 2000-04-05 NO NO20001744A patent/NO327233B1/no not_active IP Right Cessation
- 2000-08-15 US US09/639,377 patent/US6362173B1/en not_active Expired - Lifetime
-
2006
- 2006-10-05 CY CY20061101439T patent/CY1106330T1/el unknown
-
2008
- 2008-10-21 JP JP2008271442A patent/JP2009051858A/ja not_active Withdrawn
-
2009
- 2009-03-23 JP JP2009071039A patent/JP5180125B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2268792T3 (es) | 2007-03-16 |
| DK1023074T3 (da) | 2006-11-06 |
| JP5180125B2 (ja) | 2013-04-10 |
| NO20001744L (no) | 2000-04-05 |
| KR20010024431A (ko) | 2001-03-26 |
| NZ503250A (en) | 2001-09-28 |
| KR100804558B1 (ko) | 2008-02-20 |
| DE69835225D1 (de) | 2006-08-24 |
| AU747956B2 (en) | 2002-05-30 |
| CN1187053C (zh) | 2005-02-02 |
| NO327233B1 (no) | 2009-05-18 |
| PT1023074E (pt) | 2006-12-29 |
| NO20001744D0 (no) | 2000-04-05 |
| JP2009051858A (ja) | 2009-03-12 |
| JP2001518509A (ja) | 2001-10-16 |
| CN1528315A (zh) | 2004-09-15 |
| EP1023074A1 (de) | 2000-08-02 |
| KR100840957B1 (ko) | 2008-06-24 |
| CA2302586A1 (en) | 1999-04-15 |
| IL135469A (en) | 2007-03-08 |
| CN1919199A (zh) | 2007-02-28 |
| JP2009132743A (ja) | 2009-06-18 |
| CN1272788A (zh) | 2000-11-08 |
| IL135469A0 (en) | 2001-05-20 |
| US6150349A (en) | 2000-11-21 |
| US6362173B1 (en) | 2002-03-26 |
| AU9683298A (en) | 1999-04-27 |
| KR20070032822A (ko) | 2007-03-22 |
| CA2302586C (en) | 2008-06-10 |
| DE69835225T2 (de) | 2007-07-05 |
| CY1106330T1 (el) | 2011-10-12 |
| WO1999017779A1 (en) | 1999-04-15 |
| EP1023074B1 (de) | 2006-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE332696T1 (de) | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen | |
| ATE317699T1 (de) | Glucocorticoid receptor antagonisten zur behandlung von demenz | |
| ATE406166T1 (de) | Verfahren zur prävention von gewichtszunahme infolge von antipsychotika | |
| ATE252560T1 (de) | Steroidrezeptor-modulator verbindungen und methoden | |
| BG106142A (en) | Glucocorticoid receptor modulators | |
| NO20034232L (no) | Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser | |
| ATE529116T1 (de) | Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect) | |
| DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
| TNSN03133A1 (en) | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators | |
| ECSP034860A (es) | 5-sustituidas-2-arilpiridinas como moduladores del factor 1 de liberación de corticotropina | |
| NO20073369L (no) | Modulatorer av muskarinreseptorer | |
| HK1047050A1 (zh) | 治疗轻度智力机能缺陷的方法 | |
| DK1467762T3 (da) | Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis | |
| ATE411013T1 (de) | Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom | |
| IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
| NO20006320L (no) | Cykliske somatostatin-analoger | |
| ATE492281T1 (de) | Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium | |
| EA200300537A1 (ru) | Антагонисты гистаминовых рецепторов | |
| ATE380048T1 (de) | Behandlung der männlichen sexuellen dysfunktion | |
| IS5142A (is) | Kínoxalíndíón | |
| ATE408144T1 (de) | Assays | |
| ATE342055T1 (de) | Verwendung von steroidalen estrogenrezeptorantagonisten zur männlichen fertilitätskontrolle | |
| ATE320005T1 (de) | Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor | |
| DE60321354D1 (de) | Selektive d1/d5 rezeptorantagonisten zur behandlung von fettleibigkeit und von zns störungen | |
| BR0314031A (pt) | Tratamento de rinite não-alérgica por inibidores seletivos de fosfodiesterase 4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1023074 Country of ref document: EP |